Codon optimization and ubiquitin conjugation of human immunodeficiency virus-1 Tat lead to enhanced cell-mediated immune responses

Vaccine

Volumn 22, Issue 20, 2004, Pages 2586-2598

  Ramakrishna, Lakshmi ^a   Anand, Krishnamurthy Kumar ^a   Mahalingam, Marthandan ^a   Mohankumar, Kumarasamypet M ^a   Ramani, Shilpa ^b   Siddappa, Nagadenahalli B ^a   Ranga, Udaykumar ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

DNA vaccine; HIV 1 subtype C Tat; Molecular adjuvant

Indexed keywords

ADJUVANT; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LEAD; TRANSACTIVATOR PROTEIN; UBIQUITIN CONJUGATING ENZYME; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CODON USAGE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLYSIS; ENZYME ACTIVITY; GENE EXPRESSION; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; STIMULATION; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CODON; EPITOPES; HIV-1; HUMANS; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; UBIQUITIN; VACCINES, CONJUGATE;

EID: 2942620236     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.12.007     Document Type: Article

References (59)

1. Osmanov S., Heyward W.L., Esparza J. HIV-1 genetic variability: implications for the development of HIV vaccines. Antibiot. Chemother. 48:1996;30-38
2. Ho D.D., Huang Y. The HIV-1 vaccine race. Cell. 110(2):2002;135-138
3. Calarota S.A., Leandersson A.C., Bratt G., Hinkula J., Klinman D.M., Weinhold K.J., et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J. Immunol. 163(4):1999;2330-2338
4. Evans T.G., Keefer M.C., Weinhold K.J., Wolff M., Montefiori D., Gorse G.J., et al. A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+ Cytotoxic T Lymphocyte Responses in Seronegative Volunteers. J. Infect. Dis. 180(2):1999;290-298
5. Putkonen P., Quesada-Rolander M., Leandersson A., Schwartz S., Thorstensson R., Okuda K., et al. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology. 250:1998;293-301
6. Goldstein G., Manson K., Tribbick G., Smith R. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV(33)). Vaccine. 18(25):2000;2789-2795
7. Boykins R.A., Ardans J.A., Wahl L.M., Lal R.B., Yamada K.M., Dhawan S. Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice. Peptides. 21(12):2000;1839-1847
8. Ensoli B., Cafaro A. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine. J. Biol. Regul. Homeost. Agents. 14(1):2000;22-26
9. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W., et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc. Natl. Acad. Sci. USA. 97(7):2000;3515-3519
10. Caselli E., Betti M., Grossi M.P., Balboni P.G., Rossi C., Boarini C., et al. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J. Immunol. 162(9):1999;5631-5638
11. Hinkula J., Svanholm C., Schwartz S., Lundholm P., Brytting M., Engstrom G., et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J. Virol. 71(7):1997;5528-5539
12. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine. 19(20-22):2001;2862- 2877
13. Allen T.M., Mortara L., Mothe B.R., Liebl M., Jing P., Calore B., et al. Tat-Vaccinated Macaques Do Not Control Simian Immunodeficiency Virus SIVmac239 Replication. J. Virol. 76(8):2002;4108-4112
14. Hel Z., Johnson J., Tryniszewska E., Tsai W., Harrod R., Fullen J., et al. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine. 20(25-26):2002;3171-3186
15. van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol. 78(Pt 8):1997;1913-1918
16. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothe B.R., Vogel T.U., et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 407(6802):2000;386-390
17. Lamhamedi-Cherradi S., Culmann-Penciolelli B., Guy B., Kieny M., Dreyfus F., Saimot A., et al. Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS. 6:1992;1249-1258
18. Calarota S.A., Kjerrstrom A., Islam K.B., Wahren B. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum. Gene Ther. 12(13):2001;1623-1637
19. Billaut-Mulot O., Idziorek T., Loyens M., Capron A., Bahr G.M. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. Vaccine. 19(20-22):2001;2803-2811
20. Caputo A., Betti M., Altavilla G., Bonaccorsi A., Boarini C., Marchisio M., et al. Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine. 20(17-18):2002;2303-2317
21. Grant E.P., Michalek M.T., Goldberg A.L., Rock K.L. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol. 155(8):1995;3750-3758
22. Wu Y., Kipps T.J. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T-lymphocytes. J. Immunol. 159(12):1997;6037-6043
23. Tobery T., Siliciano R.F. Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J. Immunol. 162(2):1999;639-642
24. Rodriguez F., An L.L., Harkins S., Zhang J., Yokoyama M., Widera G., et al. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J. Virol. 72(6):1998;5174-5181
25. Rodriguez F., Zhang J., Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71(11):1997;8497-8503
26. Delogu G., Howard A., Collins F.M., Morris S.L. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect. Immun. 68(6):2000;3097-3102
27. Sykes K.F., Johnston S.A. Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses. DNA Cell Biol. 18(7):1999;521-531
28. *0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine. J. Immunol. 168(1):2002;379-391
29. Sharp P.M., Cowe E., Higgins D.G., Shields D.C., Wolfe K.H., Wright F. Codon usage patterns in Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens a review of the considerable within-species diversity. Nucleic Acids Res. 16(17):1988;8207-8211
30. Sharp P.M., Averof M., Lloyd A.T., Matassi G., Peden J.F. DNA sequence evolution: the sounds of silence. Philos. Trans. R. Soc. Lond. B Biol. Sci. 349(1329):1995;241-247
31. Nakamura Y., Gojobori T., Ikemura T. Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. 28(1):2000;292
32. Cullen B.R., Malim M.H. Secreted placental alkaline phosphatase as a eukaryotic reporter gene. Methods Enzymol. 216:1992;362-368
33. Sambrook J, Russel DW. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 2001.
34. Varshavsky A., Turner G., Du F., Xie Y. The ubiquitin system and the N-end rule pathway. Biol. Chem. 381(9-10):2000;779-789
35. Addo M.M., Altfeld M., Rosenberg E.S., Eldridge R.L., Philips M.N., Habeeb K., et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. USA. 98(4):2001;1781-1786
36. Imami N., Pires A., Hardy G., Wilson J., Gazzard B., Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 76(18):2002;9011-9023
37. Barker E., Mackewicz C.E., Levy J.A. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival. Proc. Natl. Acad. Sci. U.S.A. 92(24):1995;11135-11139
38. Ngo-Giang-Huong N., Candotti D., Goubar A., Autran B., Maynart M., Sicard D., et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res. Hum. Retroviruses. 17(15):2001;1435-1446
39. Cao J., McNevin J., Malhotra U., McElrath M.J. Evolution of CD8(+) T cell immunity and viral escape following acute HIV-1 infection. J. Immunol. 171(7):2003;3837-3846
40. Krone W.J., Debouck C., Epstein L.G., Heutink P., Meloen R., Goudsmit J. Natural antibodies to HIV-Tat epitopes and expression of HIV-1 genes in vivo. J. Med. Virol. 26(3):1988;261-270
41. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1(4):1998;282-292
42. Reiss P., Lange J.M., De Ronde A., de Wolf F., Dekker J., Debouck C., et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J. Med. Virol. 30(3):1990;163-168
43. Agwale S.M., Shata M.T., Reitz M.S. Jr., Kalyanaraman V.S., Gallo R.C., Popovic M., et al. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice. Proc. Natl. Acad. Sci. USA. 99(15):2002;10037-10041
44. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 5(6):1999;643-650
45. Dominici S., Laguardia M.E., Serafini G., Chiarantini L., Fortini C., Tripiciano A., et al. Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. Vaccine. 21(17-18):2003;2073-2081
46. Gringeri A., Santagostino E., Muca-Perja M., Le Buanec H., Bizzini B., Lachgar A., et al. Tat toxoid as a component of a preventive vaccine in seronegative subjects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20(4):1999;371-375
47. Tikhonov I., Ruckwardt T.J., Hatfield G.S., Pauza C.D. Tat-neutralizing antibodies in vaccinated macaques. J. Virol. 77(5):2003;3157-3166
48. Osterhaus A.D., van Baalen C.A., Gruters R.A., Schutten M., Siebelink C.H., Hulskotte E.G., et al. Vaccination with Rev and Tat against AIDS. Vaccine. 17(20-21):1999;2713-2714
49. Caputo A., Grossi M.P., Bozzini R., Rossi C., Betti M., Marconi P.C., et al. Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region. Gene Ther. 3(3):1996;235-245
50. Tobery T.W., Siliciano R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T-lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185(5):1997;909-920
51. Hauber J., Malim M.H., Cullen B.R. Mutational analysis of the conserved basic domain of human immunodeficiency virus Tat protein. J. Virol. 63(3):1989;1181-1187
52. Rice A.P., Carlotti F. Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J. Virol. 64(4):1990;1864-1868
53. Fu T.M., Guan L., Friedman A., Ulmer J.B., Liu M.A., Donnelly J.J. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vaccine. 16(18):1998;1711-1717
54. Townsend A., Bastin J., Gould K., Brownlee G., Andrew M., Coupar B., et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168(4):1988;1211-1224
55. Liu W.J., Zhao K.N., Gao F.G., Leggatt G.R., Fernando G.J., Frazer I.H. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine. 20(5-6):2001;862-869
56. Vidalin O., Tanaka E., Spengler U., Trepo C., Inchauspe G. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol. 18(8):1999;611-621
57. McPhee D.A., Kemp B.E., Cumming S., Stapleton D., Gust I.D., Doherty R.R. Recognition of envelope and Tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS Lett. 233(2):1988;393-396
58. Novitsky V., Rybak N., McLane M.F., Gilbert P., Chigwedere P., Klein I., et al. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J. Virol. 75(19):2001;9210-9228
59. Ranki A., Suni J., Blazevic V., Holmstrom P., Mattinen S., Krohn K., et al. T-cell recognition of HIV antigens in HIV-seroreverted persons. AIDS. 11(1):1997;132-133